Nasus Pharma Ltd. NSRX
2.94 USD +0.12 (+4.08%)
Nov 9, 2026, 3:58 PM EST
2.76 Day range 2.96
1.98 52-week range 9.50
- YTD
- -67.92%
- 1 year
- -60.87%
- Market cap
- 34.38M
- EPS (ttm)
- -1.20
- YTD return
- -67.92%
- 1-year return
- -60.87%
- Volume
- 17.56K
- Avg volume
- 17.25K
- Open
- 2.76
- Previous close
- 2.82
- Day's range
- 2.76 – 2.96
- 52-week range
- 1.98 – 9.50
5D -0.28 (-9.03%)
Financials — quick view
NSRX Revenue — annual 0
NSRX Net income — annual -5.86M
NSRX EPS — annual -0.72
News
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday 
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7 
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate 
Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27 
Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Friday's After-Market Session 
Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18 
Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4 - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on NSRX — it syncs with the Stock Master app.